Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.51 |
| ▸ | DRD3 | P35462 | 8/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852297 | 0.91 | DRD2 (0.56) | DRD2DRD3DRD4ALDH1A1GAA | |
| SCHEMBL3120693 | 0.89 | DRD2 (0.50) | DRD2DRD3DRD4ALDH1A1GAA | |
| SCHEMBL3124228 | 0.87 | DRD2 (0.54) | DRD2DRD3DRD4CCR1 | |
| SCHEMBL3107392 | 0.86 | DRD2 (0.42) | DRD2DRD3DRD4ALDH1A1GAA | |
| SCHEMBL3123011 | 0.86 | DRD2 (0.42) | DRD2DRD3DRD4ALDH1A1KMT2A | |
| SCHEMBL3126014 | 0.85 | DRD2 (0.48) | DRD2DRD3DRD4CCR1OPRL1 | |
| SCHEMBL3856142 | 0.83 | DRD2 (0.58) | DRD2DRD3DRD4CCR1PNMT | |
| SCHEMBL3120562 | 0.83 | DRD2 (0.47) | DRD2DRD3DRD4ALDH1A1GAA | |
| SCHEMBL3119638 | 0.82 | DRD2 (0.48) | DRD2DRD3DRD4CCR1OPRL1 | |
| SCHEMBL3121760 | 0.81 | DRD2 (0.46) | DRD2DRD3DRD4ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155671-B1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2017-12-20 | — | — | EP | claimed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | claimed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | claimed |
| EP-2155671-A2 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | claimed |
| WO-2008148801-A2 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | claimed |
| EP-2155671-B1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | disclosed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, DBH, SLC6A2 | DRD2 9/4885DRD3 24/4885DRD4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.